Literature DB >> 16352706

Fatty acid amide hydrolase (-/-) mice exhibit an increased sensitivity to the disruptive effects of anandamide or oleamide in a working memory water maze task.

Stephen A Varvel1, Benjamin F Cravatt, April E Engram, Aron H Lichtman.   

Abstract

Although recent evidence suggests that fatty acid amide hydrolase (FAAH) may represent a potential therapeutic target, few published studies have investigated FAAH or its fatty acid amide substrates (FAAs) in animal models of learning and memory. Therefore, our primary goal was to determine whether FAAH (-/-) mice, which possess elevated levels of anandamide and other FAAs, would display altered performance in four Morris water maze tasks: acquisition of a hidden fixed platform, reversal learning, working memory, and probe trials. FAAH (-/-) mice failed to exhibit deficits in any task; in fact, they initially acquired the working memory task more rapidly than FAAH (+/+) mice. The second goal of this study was to investigate whether the FAAH inhibitor OL-135 (1-oxo-1[5-(2-pyridyl)-2-yl]-7-phenylheptane), anandamide, other FAAs, and methanandamide would affect working memory in both genotypes. FAAH (-/-), but not (+/+), mice displayed working memory impairments following exogenous administration of anandamide (ED(50) = 6 mg/kg) or oleamide (50 mg/kg). However, the central cannabinoid receptor (CB(1)) receptor antagonist SR141716 [N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl] only blocked the disruptive effects of anandamide. Methanandamide, which is not metabolized by FAAH, disrupted working memory performance in both genotypes (ED(50) = 10 mg/kg), suggesting that CB(1) receptor signaling is unaltered by FAAH deletion. In contrast, OL-135 and other FAAs failed to affect working memory in either genotype. These results suggest that FAAH deletion does not impair spatial learning but may enhance acquisition under certain conditions. More generally, FAAH may represent a novel therapeutic target that circumvents the undesirable cognitive side effects commonly associated with direct-acting cannabinoid agonists.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16352706     DOI: 10.1124/jpet.105.095059

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  21 in total

Review 1.  Anandamide and 2-arachidonoylglycerol: pharmacological properties, functional features, and emerging specificities of the two major endocannabinoids.

Authors:  Antonio Luchicchi; Marco Pistis
Journal:  Mol Neurobiol       Date:  2012-07-17       Impact factor: 5.590

2.  Pharmacological elevation of anandamide impairs short-term memory by altering the neurophysiology in the hippocampus.

Authors:  Anushka V Goonawardena; John Sesay; Cheryl Ann Sexton; Gernot Riedel; Robert E Hampson
Journal:  Neuropharmacology       Date:  2011-07-13       Impact factor: 5.250

3.  delta(9)-Tetrahydrocannabinol-dependent mice undergoing withdrawal display impaired spatial memory.

Authors:  Laura E Wise; Stephen A Varvel; Dana E Selley; Jason M Wiebelhaus; Kelly A Long; Lisa S Middleton; Laura J Sim-Selley; Aron H Lichtman
Journal:  Psychopharmacology (Berl)       Date:  2011-05-11       Impact factor: 4.530

4.  Phenotypic assessment of THC discriminative stimulus properties in fatty acid amide hydrolase knockout and wildtype mice.

Authors:  D Matthew Walentiny; Robert E Vann; Jenny L Wiley
Journal:  Neuropharmacology       Date:  2015-02-16       Impact factor: 5.250

Review 5.  Endocannabinoid system in neurodegenerative disorders.

Authors:  Balapal S Basavarajappa; Madhu Shivakumar; Vikram Joshi; Shivakumar Subbanna
Journal:  J Neurochem       Date:  2017-07-05       Impact factor: 5.372

6.  Chronic Delta9-tetrahydrocannabinol during adolescence increases sensitivity to subsequent cannabinoid effects in delayed nonmatch-to-position in rats.

Authors:  Jenny L Wiley; James J Burston
Journal:  Pharmacol Biochem Behav       Date:  2009-11-24       Impact factor: 3.533

Review 7.  Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction.

Authors:  Leigh V Panlilio; Zuzana Justinova; Steven R Goldberg
Journal:  Pharmacol Ther       Date:  2013-01-16       Impact factor: 12.310

8.  A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol.

Authors:  Jacqueline L Blankman; Gabriel M Simon; Benjamin F Cravatt
Journal:  Chem Biol       Date:  2007-12

9.  Dual fatty acid amide hydrolase and monoacylglycerol lipase blockade produces THC-like Morris water maze deficits in mice.

Authors:  Laura E Wise; Kelly A Long; Rehab A Abdullah; Jonathan Z Long; Benjamin F Cravatt; Aron H Lichtman
Journal:  ACS Chem Neurosci       Date:  2012-01-27       Impact factor: 4.418

Review 10.  Endocannabinoids in the retina: from marijuana to neuroprotection.

Authors:  Stephen Yazulla
Journal:  Prog Retin Eye Res       Date:  2008-08-03       Impact factor: 21.198

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.